Critical appraisal of ranibizumab in the treatment of diabetic macular edema
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: Diabetic retinopathy is the leading cause of blindness among individuals of working age in industrialized nations, with most of the vision loss resulting from diabetic macular edema (DME). The forma...
Guardado en:
Autor principal: | Stewart MW |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2026073f3089400d93fa4e116c21646f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
por: Bandello F, et al.
Publicado: (2011) -
Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
por: Kim M, et al.
Publicado: (2013) -
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim LS, et al.
Publicado: (2015) -
Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
por: Keane PA, et al.
Publicado: (2011) -
Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
por: Xiu-Xian Wang, et al.
Publicado: (2021)